Crinetics Pharmaceuticals (CRNX) Accounts Payables (2017 - 2025)
Crinetics Pharmaceuticals has reported Accounts Payables over the past 9 years, most recently at $41.8 million for Q4 2025.
- For Q4 2025, Accounts Payables rose 94.56% year-over-year to $41.8 million; the TTM value through Dec 2025 reached $41.8 million, up 94.56%, while the annual FY2025 figure was $41.8 million, 94.56% up from the prior year.
- Accounts Payables for Q4 2025 was $41.8 million at Crinetics Pharmaceuticals, up from $33.7 million in the prior quarter.
- Over five years, Accounts Payables peaked at $41.8 million in Q4 2025 and troughed at $3.4 million in Q4 2021.
- A 5-year average of $15.8 million and a median of $11.0 million in 2022 define the central range for Accounts Payables.
- Biggest five-year swings in Accounts Payables: crashed 77.48% in 2024 and later surged 581.8% in 2025.
- Year by year, Accounts Payables stood at $3.4 million in 2021, then soared by 348.6% to $15.4 million in 2022, then skyrocketed by 51.1% to $23.2 million in 2023, then decreased by 7.45% to $21.5 million in 2024, then skyrocketed by 94.56% to $41.8 million in 2025.
- Business Quant data shows Accounts Payables for CRNX at $41.8 million in Q4 2025, $33.7 million in Q3 2025, and $38.1 million in Q2 2025.